The choice of first line therapy for RAS wild type metastatic colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2015.04.07

Abstract

Abstract:

The introduction of new chemotherapeutics and monoclonal antibodies into the treatment protocols for advanced CRC has significantly improved the outcomes.Oncologists have a wide range of agents to choose for the treatment of advanced CRC; however, their optimal administration remains unclear.This article presents recent data from the trials evaluating the use of monoclonal antibodies in advanced CRC.

Key words: Colorectal neoplasms, Neoplasm metastasis, First line therapy

Cong LUO, Jie-er YING. The choice of first line therapy for RAS wild type metastatic colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2015, 04(04): 380-384.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2015.04.07

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2015/V04/I04/380

References 17

[1]	Center MM, Jemal A, Smith RA, et al.Worldwide variations in colorectal cancer.CA Cancer J Clin, 2009, 59(6): 366-378.
[2]	Hurwitz H, Fehrenbacher L, Novotny W, et al.Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med, 2004, 350: 2335-2342.
[3]	Guan ZZ, Xu JM, Luo RC, et al.Efficacy and safety of Bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: A randomized phase III ARTIST trial.Chin J Cancer, 2011, 30: 682-689.
[4]	Saltz LB, Clarke S, Díaz-Rubio E, et al.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study.J Clin Oncol, 2008, 26: 2013-2019.
[5]	Díaz-Rubio E, Gómez-España A, Massutí B, et al.First-line XELOX plus Bevacizumab followed by XELOX plus Bevacizumab or single-agent Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.Oncologist, 2012, 17(1): 15-25.
[6]	Koopman M, Simkens L, Ten Tije AJ, et al.Maintenance treatment with capecitabine and Bevacizumab versus observation after induction treatment with chemotherapy and Bevacizumab in metastatic colorectal cancer(mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group(DCCG). Lancet, 2015, 385(9980): 1843-1852.
[7]	Senellart H, Hiret S, Guerin-Meyer V, et al.Use of maintenance therapy and complete discontinuation for therapeutic management of non-resectable metastatic colorectal cancer.Bull Cancer, 2014, 101(6): 619-625.
[8]	Cutsem EV, Nowacki M, Lang I, et al.Randomized phase Ⅲstudy of irinotecan and 5-FU/FA with orwithoutcetuximab in thefirst-line treat ment of patients with metastatic colorectal cancer(mCRC): the CRYSTAL trial.J Clin Oncol, 2007, 25(18): 4000.
[9]	Bokemeyer C, Bondarenko I, Makhson A, et al.Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.J Clin Oncol, 2009, 27: 663-671.
[10]	Maughan TS, Adams RA, Smith CG, et al.Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.Lancet, 2011, 377(9783): 2103-2114.
[11]	Tveit KM, Guren T, Glimelius B, et al.Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin(Nordic FLOX)versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.J Clin Oncol, 2012, 30(15): 1755-1762.
[12]	Douillard JY, Siena S, Cassidy J, et al.Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin(FOLFOX4)versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.J Clin Oncol, 2010, 28(31): 4697-4705.
[13]	Douillard JY, Siena S, Cassidy J, et al.Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer.Ann Oncol, 2014, 25(7): 1346-1355.
[14]	Stintzing S, Fischer von Weikersthal L, Decker T, et al.FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastaticcolorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.Ann Oncol, 2012, 23(7): 1693-1699.
[15]	Venook AP, Niedzwiecki D, Lenz HJ, et al.CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin(FOLFIRI)or oxaliplatin/5-FU/leucovorin(mFOLFOX6)with Bevacizumab(BV)or cetuximab(CET)for patients(pts)with KRAS wild-type(wt)untreated metastatic adenocarcinoma of the colon or rectum(MCRC).2014 American Society of Clinical Oncology(ASCO)Annual Meeting.
[16]	Primrose J, Falk S, Finch-Jones M, et al.Systemic chemotherapy with or without cetuximab in patients with resectablecolorectal liver metastasis: the New EPOC randomised controlled trial.Lancet Oncol, 2014, 15(6): 601-611.
[17]	Nordlinger B, Poston GJ, Goldberg RMShould the results of the new EPOC trial change practice in the management of patients with resectable metastatic colorectal cancer confined to the liver? .J Clin Oncol, 2015, 33(3): 241-243.

Please choose a citation manager

Content to export